- Details
- (Length of Discussion: 22 min) Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial , in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeti...
|
- Details
- Christopher Payne, MD a urologist from San Jose, California and Diane Newman, DNP discuss several presentations from the 2018 Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction meeting (SUFU). Among the topics, they highlight are Urinary Bladder Dysfunction, Bladder Innervation, Stress Urinary Incontinence (SUI) and Lower Urinary Tract Infections. They overview several pr...
|
- Details
- Diane Newman welcomes viewers to the Pelvic health Center of Excellence on UroToday.com The leading location for state of the art lectures, original articles, research, current treatments and emerging clinical care in pelvic health and pelvic floor dysfunction. Diane encourages viewers to utilize this center as a resource for current research, clinical expertise and to stay up to date with current...
|
- Details
- (Length of Presentation: 27 min) Jeffrey Weiss, presents the pathophysiology of nocturia and describes important steps in the evaluation of nocturia. Two case reports are presented. Final thoughts are included on nocturnal polyuria, replacement therapy, overnight fluid deprivation tests, behavioral therapy and more. Biography: Jeffrey P. Weiss, MD, FACS is a urologist in Brooklyn, New York and is...
|
- Details
- (Length of Discussion: 25 min) Professor Eric Small, MD talks with Dr. Neal Shore in a post ASCO GU interview on Dr. Eric Small’s plenary presentation on the phase three global SPARTAN trial. A landscape changing treatment for patients with non-metastatic castration resistant prostate cancer. The first drug approved by FDA to satisfy an unmet need for nmCRPC or m0 patients. Dr. Eric Small gives an...
|
- Details
- Robert Hamilton, a Staff Urologic Oncologist from Princess Margaret Cancer Centre in Toronto, Canada discusses radical prostatectomy for patients with oligometastatic prostate cancer. He overviews the clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging. He reviews four major PET tracers receiving a lot of attention: PS...
|
- Details
- (Length of Discussion: 40 sec) Dr. Phil Febbo, chief medical officer of Genomic Health, discusses a new test to guide treatment in metastatic prostate cancer. Read More: Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test Expands Offering to Prostate Cancer Patients - Predicting Treatment Response in Metastatic Disease Biography: Phil Febbo, M.D. Chief Medical Officer After 20 years as a physician s...
|
- Details
- (Length of Discussion 21 min) Jeannette Potts presents the causes and treatments of nocturia. Nocturia, the most common lower urinary tract symptom is a condition in which a patient expereinces nighttime awakening to void. Nocturia affects approximately 70-75% of adults over 40 years of age. She reviews multiple symptoms causes by nocturnal polyuria including chronic fatigue, depression, hypertens...
|
- Details
- (Length of Conversation: 19 min) Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, pa...
|
- Details
- (Length of Discussion: 15 min) Lawrence I Karsh discusses SpaceOAR Hydrogel and it's use as a prostate-rectum spacer for treating prostate cancer with radiation therapy. He presents a study he took part in which aimed to evaluate the safety of the prostate-rectum spacer application technique as well as the following: the implant quality and resulting rectal dose reduction, acute and long term rect...
|
